Is there a future for AKT inhibitors in the treatment of cancer?

Valerie M. Jansen, Ingrid A. Mayer, Carlos L. Arteaga

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER+/HER2- breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway.

Original languageEnglish (US)
Pages (from-to)2599-2601
Number of pages3
JournalClinical Cancer Research
Volume22
Issue number11
DOIs
StatePublished - Jun 1 2016

Fingerprint

Estrogen Receptor Modulators
Phosphatidylinositol 3-Kinases
Neoplasms
Breast Neoplasms
Therapeutics
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Is there a future for AKT inhibitors in the treatment of cancer? / Jansen, Valerie M.; Mayer, Ingrid A.; Arteaga, Carlos L.

In: Clinical Cancer Research, Vol. 22, No. 11, 01.06.2016, p. 2599-2601.

Research output: Contribution to journalArticle

Jansen, Valerie M. ; Mayer, Ingrid A. ; Arteaga, Carlos L. / Is there a future for AKT inhibitors in the treatment of cancer?. In: Clinical Cancer Research. 2016 ; Vol. 22, No. 11. pp. 2599-2601.
@article{a99f6c96f38d43a883383cb553c38537,
title = "Is there a future for AKT inhibitors in the treatment of cancer?",
abstract = "An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER+/HER2- breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway.",
author = "Jansen, {Valerie M.} and Mayer, {Ingrid A.} and Arteaga, {Carlos L.}",
year = "2016",
month = "6",
day = "1",
doi = "10.1158/1078-0432.CCR-16-0100",
language = "English (US)",
volume = "22",
pages = "2599--2601",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "11",

}

TY - JOUR

T1 - Is there a future for AKT inhibitors in the treatment of cancer?

AU - Jansen, Valerie M.

AU - Mayer, Ingrid A.

AU - Arteaga, Carlos L.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER+/HER2- breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway.

AB - An AKT inhibitor plus an antiestrogen exhibited no significant clinical activity in patients with ER+/HER2- breast cancer despite laboratory studies supporting an antitumor effect for both drugs combined. These results raise concerns about the development of AKT inhibitors in unselected patients whose tumors have unknown dependence on the PI3K/AKT pathway.

UR - http://www.scopus.com/inward/record.url?scp=84971532172&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84971532172&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-0100

DO - 10.1158/1078-0432.CCR-16-0100

M3 - Article

C2 - 26979397

AN - SCOPUS:84971532172

VL - 22

SP - 2599

EP - 2601

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 11

ER -